Viatris wins RYZUMVI approval: UBS sets USD 26 target for Viatris stock

Published on 10/20/2026 at 14:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

FDA approval broadens Viatris' eye-care portfolio. Viatris stock trades at EUR 16.31 on October 20, 2026 as Q2 revenue reached USD 3.76 billion.

Acquisition and reporting calendar

Viatris agreed to acquire Pacira for USD 1.65 billion on October 8, 2026.
Second-quarter 2026 revenue reached USD 3.76 billion, while GAAP net loss was USD 118.8 million.
Viatris stock trades at EUR 16.31 at 2:05 p.m. CEST at Lang & Schwarz on October 20, 2026.
Third-quarter 2026 results are scheduled for November 5, 2026.

Flatlay-Aufnahme mit ISIN-Karte, Klappe, Filmrolle, Drehbuch und Popcorntüte auf Holztisch — Paramount Global (US92556V1061) Flatlay mit ISIN-Karte, Filmklappe, Filmrolle, Skript und Popcorn-Tüte arrangiert, Illustration mit AI erstellt.

Viatris (ISIN US92556V1061) trades at EUR 16.31 at Lang & Schwarz on October 20, 2026, while its latest corporate catalyst is the FDA approval of RYZUMVI for adult presbyopia. Viatris listed the approval on October 16, 2026, and the company is also pursuing a broader shift toward branded medicines.

Why RYZUMVI matters

The approval expands RYZUMVI beyond its earlier use for pharmacologically induced mydriasis and gives Viatris a wider ophthalmology opportunity. The product is a 0.75 percent phentolamine ophthalmic solution, according to Simply Wall St on October 18, 2026. The commercial test will be prescription growth, not the approval alone.

Three dates changed the story

On June 30, 2026, Viatris reported second-quarter revenue of USD 3.76 billion, up from USD 3.58 billion a year earlier, while GAAP net loss widened to USD 118.8 million from USD 4.6 million, according to Markets Insider. On October 8, 2026, the company agreed to acquire Pacira BioSciences for USD 1.65 billion in cash. On October 16, 2026, the FDA approved the expanded RYZUMVI indication.

What does the deal mean for growth?

The Pacira transaction adds the non-opioid pain medicines EXPAREL and ZILRETTA to Viatris' portfolio. Pacira generated USD 746 million in revenue and USD 177 million in adjusted EBITDA in the twelve months ended June 30, 2026, according to the transaction analysis. That combination gives investors a measurable test of whether branded products can offset pressure on mature generics.

Next reporting date

Viatris plans to report third-quarter 2026 financial results on November 5, 2026, at 8:30 a.m. EST, according to the company's investor-relations calendar. The report should provide the next quantified read on integration spending, cash generation and the contribution from newer products.

Analyst targets remain divided

UBS raised its Viatris price target from USD 23.00 to USD 26.00 while maintaining a Buy rating in a report dated October 5, 2026, as reported by Markets Insider. Piper Sandler later kept a Hold rating with a USD 13.00 target, while Bank of America Securities maintained a Sell rating with a USD 16.00 target on October 12, 2026. Viatris' market capitalization was USD 20.93 billion on October 16, 2026, and the Nasdaq-listed stock had a USD 9.92 to USD 18.43 52-week range.

Price and investor perspective

The current setup combines a fresh ophthalmology approval, a USD 1.65 billion acquisition and a clear disagreement among analysts. For investors, the November report will show whether the portfolio expansion is translating into operating progress.

Viatris was trading at EUR 16.31 at Lang & Schwarz on October 20, 2026 at 2:05 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Viatris stock.